Ofatumumab is a fully human monoclonal antibody targeting the CD20 antigen on B lymphocytes. It functions primarily through the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), effectively lysing CD20-positive B cells. This antibody demonstrates potent efficacy in eliminating CD20-positive tumor cells, including those resistant to other drugs with low CD20 expression levels. Ofatumumab is particularly valuable in the study of chronic lymphocytic leukemia (CLL), offering insights into therapeutic resistance and disease progression mechanisms.
Ofatumumab is a fully human monoclonal antibody targeting the CD20 antigen on B lymphocytes. It functions primarily through the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), effectively lysing CD20-positive B cells. This antibody demonstrates potent efficacy in eliminating CD20-positive tumor cells, including those resistant to other drugs with low CD20 expression levels. Ofatumumab is particularly valuable in the study of chronic lymphocytic leukemia (CLL), offering insights into therapeutic resistance and disease progression mechanisms.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
